Prevention of microalbuminuria in patients with type 2 diabetes and hypertension

Journal of Hypertension

Volumn 30, Issue 4, 2012, Pages 811-818

  Menne, Jan ^a   Izzo, Joseph L ^b   Ito, Sadayoshi ^c   Januszewicz, Andrzej ^d   Katayama, Shigehiro ^e   Chatzykirkou, Christos ^a   Mimran, Albert ^f   Rabelink, Ton J ^g   Ritz, Eberhard ^h   Ruilope, Luis M ⁱ   Rump, Lars C ^j   Viberti, Giancarlo ^k   Haller, Hermann ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY AT BUFFALO   (United States)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d INSTITUTE OF CARDIOLOGY   (Poland)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

^f LAPEYRONIE HOSPITAL   (France)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^j HEINRICH HEINE UNIVERSITY   (Germany)

^k KING'S COLLEGE LONDON   (United Kingdom)

more..

Author keywords

albuminuria; angiotensin receptor blocker; diabetes; diabetic nephropathy; hypertension; microalbuminuria

Indexed keywords

ANTIHYPERTENSIVE AGENT; OLMESARTAN; PLACEBO;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 84858694202     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328351856d     Document Type: Article

References (31)

1. Menne J, Chatzikyrkou C, Haller H. Microalbuminuria as a risk factor: the influence of renin-angiotensin system blockade. J Hypertens 2010; 28:1983-1994.
2. USRDS. The United States Renal Data System. Am J Kidney Dis 2003; 42:1-230.
3. Mogensen CE. Urinary albumin excretion in early and long-term juvenile diabetes. Scand J Clin Lab Invest 1971; 28:183-193.
4. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulindependent diabetes mellitus. Lancet 1982; 1:1430-1432. (Pubitemid 12123979)
5. de Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol 2006; 17:2100-2105. (Pubitemid 44141898)
6. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187. (Pubitemid 46924065)
7. American Diabetes Association (no author name is mentioned) Standards of medical care in diabetes: 2009. Diabetes Care 2009; 32(Suppl 1):S13-S61.
8. Ochodnicky P, Henning RH, van Dokkum RP, de Zeeuw D. Microalbuminuria and endothelial dysfunction: emerging targets for primary prevention of end-organ damage. J Cardiovasc Pharmacol 2006; 47 (Suppl 2):S151-S162; discussion S72-S76. (Pubitemid 44620205)
9. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.AmJ Kidney Dis 2000; 36:646-661.
10. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
11. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
12. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351:1941-1951. (Pubitemid 39447135)
13. Haller H, Ito S, Izzo JL,Jr, Januszewicz A, Katayama S, Menne J, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907-917.
14. Haller H, Viberti GC, Mimran A, Remuzzi G, Rabelink AJ, Ritz E, et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens 2006; 24:403-408. (Pubitemid 43348255)
15. Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010; 303:423-429.
16. Gansevoort RT, de Jong PE. The case for using albuminuria in staging chronic kidney disease. J Am Soc Nephrol 2009; 20:465-468.
17. Hallan SI, Ritz E, Lydersen S, Romundstad S, Kvenild K, Orth SR. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 2009; 20:1069-1077.
18. Andersen S, Brochner-Mortensen J, Parving HH. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diab Care 2003; 26:3296-3302. (Pubitemid 37466890)
19. Bilous R, Chaturvedi N, Sjolie AK, Fuller J, Klein R, Orchard T, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009; 151:11-20; W3-W4.
20. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575-1585.
21. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110:1103-1107. (Pubitemid 39319009)
22. The North Tyneside Diabetes Team. The diabetes annual review as an educational tool: assessment and learning integrated with care, screening, and audit. Diabet Med 1992; 9:389-394.
23. Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol 2006; 17:3472-3481. (Pubitemid 44865289)
24. de Galan BE, Perkovic V, Ninomiya T, Pillai A, Patel A, Cass A, et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009; 20:883-892.
25. Benicar (olmesartan). Ongoing safety review. (2011). http://www.fda gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedi calProducts/ucm215249htm. [Accessed 14 April 2011].
26. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbaek A, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011; 378:156-167.
27. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of causespecific death. N Engl J Med 2011; 364:829-841.
28. Preiss D, Sattar N, McMurray JJ, Mancia G, Gao P, Fagard R, et al. A systematic review of event rates in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. Am Heart J 2011; 161:210-219.
29. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009; 27:1360-1369.
30. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144:884-893. (Pubitemid 46768128)
31. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121-2158.